Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions

BMC Pulmonary Medicine

Table 2 IC, IE and ICERs depending on the initial number of hospitalisations and exacerbations

prior n° of exac.	prior number (n°) of hospitalisations
	0						1					2
	IC		IE		ICER		IC		IE		ICER*	IC		IE		ICER*
0	428		0.0000		dominated		84		0.0008		107666	-259		0.0016		cost saving
	426	429	0.0000	0.0000			-581	819	-0.0009	0.0027		-1589	1211	-0.0017	0.0054
1	420		0.0005		1265951		77		0.0012		62094	-266		0.0020		cost saving
	416	424	0.0001	0.0008	497057	4154369	-590	812	-0.0004	0.0033		-1599	1204	-0.0013	0.0061
2	413		0.0009		622357		70		0.0017		41019	-274		0.0025		cost saving
	406	419	0.0002	0.0017	242740	2049176	-599	805	0.0000	0.0039		-1608	1196	-0.0008	0.0066
3	405		0.0014		407826		62		0.0022		28873	-281		0.0029		cost saving
	395	415	0.0003	0.0025	158255	1338516	-608	797	0.0002	0.0046		-1617	1189	-0.0003	0.0072
4	398		0.0018		300561		55		0.0026		20974	-289		0.0034		cost saving
	384	410	0.0004	0.0034	116258	983186	-618	790	0.0003	0.0053		-1626	1182	0.0000	0.0077
5	391		0.0023		236201		47		0.0031		15425	-296		0.0038		cost saving
	374	406	0.0005	0.0042	90683	769988	-627	780	0.0005	0.0061		-1635	1175	0.0003	0.0085
6	383		0.0027		193295		40		0.0035		11314	-303		0.0043		cost saving
	363	401	0.0006	0.0050	74097	627857	-634	770	0.0007	0.0068		-1645	1167	0.0004	0.0092
7	376		0.0032		162648		32		0.0040		8146	-311		0.0048		cost saving
	352	397	0.0007	0.0059	62023	529076	-641	760	0.0008	0.0076		-1654	1160	0.0006	0.0099
8	368		0.0036		139662		25		0.0044		5630	-318		0.0052		cost saving
	341	392	0.0008	0.0067	52879	456718	-650	750	0.0010	0.0084		-1663	1153	0.0007	0.0106
9	361		0.0041		121784		18		0.0049		3583	-326		0.0057		cost saving
	330	388	0.0009	0.0075	45609	400440	-659	740	0.0011	0.0092		-1672	1143	0.0008	0.0114
10	353		0.0046		107482		10		0.0053		1885	-333		0.0061		cost saving
	319	383	0.0010	0.0084	39741	355417	-667	730	0.0012	0.0100		-1681	1133	0.0010	0.0122

Exac. = exacerbations
IC: incremental cost (expressed in euro); IE: incremental effect (expressed in quality-adjusted life years (QALY) gained); ICER: incremental cost-effectiveness ratio (expressed in cost per QALY gained). In every cell, the mean value and the lower (2.5%) and upper (97.5%) limits of the interval are mentioned.
* the ICERs of the probabilistic model are not mentioned since simulation results are spread over several quadrants of the cost-effectiveness plane. As an alternative (in italics), the ICER calculated by dividing the mean incremental cost by the mean incremental benefit is presented.

ISSN: 1471-2466